Abionic | Hitting the European and US markets
22.01.2020
Share this article
Abionic to commercialise its rapid sepsis diagnosis product on the EU and US markets
The Abionic team, who has now reached over 50 members at the Biopôle in Epalinges, starts this new decade with a successful outlook.
After raising 20 million Swiss francs in 2018, enabling a succession of successful clinical trials in 2019, the EPFL spin-off founded in 2010 is now aiming to commercialise its rapid sepsis diagnosis product in Switzerland and Italy in 2020. Clinical trials are also set to take place in 2020 in the United States following the FDA approval received in 2019.
Read full AGEFI news in French